Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. 2. Preparation and in vitro and in vivo evaluation of 1-(alkoxymethyl)-2-[(hydroxyimino)methyl]-3-methylimida zolium halides for reactivation of organophosphorus-inhibited acetylcholinesterases.
A series of structurally related mono- and bis-1,3-disubstituted 2-[(hydroxyimino)methyl]imidazolium halides were evaluated in vitro for their ability to reactivate electric eel, bovine, and human erythrocyte (RBC) acetylcholinesterases (AChE) inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP) and 3,3-dimethyl-2-butyl methyl-phosphonofluoridate (soman, GD). All new compounds were characterized for (hydroxyimino)methyl acid dissociation constant, nucleophilicity, octanol-buffer partition coefficient, reversible AChE inhibition, and kinetics of reactivation of EPMP-inhibited AChEs. For GD-inhibited AChEs, maximal reactivation was used to compare compounds since rapid phosphonyl enzyme dealkylation "aging" complicated interpretation of kinetic constants. For comparison, we also evaluated three known pyridinium therapeutics, 2-PAM, HI-6, and toxogonin. In vivo evaluation in mice revealed that when selected imidazolium compounds were coadministered with atropine sulfate, they were effective in providing lifesaving protection against both GD and EPMP challenges. This was a major accomplishment in the search for effective anticholinesterase therapeutics--the synthesis and preliminary evaluation of the first new monoquaternary soman antidotes with potencies superior to 2-PAM. Significantly, there was an apparent inverse relationship between in vitro and in vivo results; the most potent in vivo compounds proved to be the poorest in vitro reactivators. These results suggested that an alternative and possibly novel antidotal mechanism of protective action may be applicable for the imidazolium aldoximes. Selected compounds were also evaluated for their inhibition of AChE phosphorylation by GD and antimuscarinic and antinicotinic receptor blocking effects.
Bedford
C D
CD
Organic Chemistry Department, SRI International, Menlo Park, California 94025.
Harris
R N
RN
Howd
R A
RA
Goff
D A
DA
Koolpe
G A
GA
Petesch
M
M
Miller
A
A
Nolen
H W
HW
Musallam
H A
HA
Pick
R O
RO
D000818:Animals; D002417:Cattle; D002801:Cholinesterase Reactivators / Q000138:chemical synthesis* / Q000494:pharmacology; D004524:Eels; D006801:Humans; D007093:Imidazoles / Q000138:chemical synthesis* / Q000494:pharmacology; D007097:Imines / Q000138:chemical synthesis* / Q000494:pharmacology; D007700:Kinetics; D051379:Mice; D009943:Organophosphorus Compounds / Q000037:antagonists & inhibitors; D011950:Receptors, Cholinergic / Q000187:drug effects; D012999:Soman / Q000037:antagonists & inhibitors; D013329:Structure-Activity Relationship
D002801:Cholinesterase Reactivators; D007093:Imidazoles; D007097:Imines; D009943:Organophosphorus Compounds; D011950:Receptors, Cholinergic; C042896:ethyl 4-nitrophenyl methylphosphonate; D012999:Soman